[English] 日本語
Yorodumi- EMDB-45969: Local refinement of the SARS-CoV-2 BA.2.86 RBD in complex with TR... -
+
Open data
-
Basic information
| Entry | ![]() | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Title | Local refinement of the SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder | |||||||||
Map data | sharpened map | |||||||||
Sample |
| |||||||||
Keywords | Sarbecoviruses / Spike glycoprotein / Structural Genomic / inhibitor / viral protein / minibinder / Structural Genomics / Seattle Structural Genomics Center for Infectious Disease / SSGCID | |||||||||
| Biological species | Sarbecovirus sp. / ![]() | |||||||||
| Method | single particle reconstruction / cryo EM / Resolution: 3.2 Å | |||||||||
Authors | Lee J / Seattle Structural Genomics Center for Infectious Disease (SSGCID) / Veesler D | |||||||||
| Funding support | United States, 1 items
| |||||||||
Citation | Journal: Commun Biol / Year: 2026Title: The computationally designed TRI2-2 miniprotein inhibitor protects against multiple SARS-CoV-2 Omicron variants. Authors: Jimin Lee / James Brett Case / Young-Jun Park / Rashmi Ravichandran / Daniel Asarnow / M Alejandra Tortorici / Jack T Brown / Shilpa Sanapala / Lauren Carter / David Baker / Michael S Diamond / David Veesler / ![]() Abstract: The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised neutralizing antibody responses elicited by prior infection or vaccination and abolished the ...The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised neutralizing antibody responses elicited by prior infection or vaccination and abolished the utility of most monoclonal antibody therapeutics. We previously described a computationally-designed, homotrimeric miniprotein inhibitor, designated TRI2-2, that protects mice against pre-Omicron SARS-CoV-2 variants. Here, we show that TRI2-2 exhibits broadly neutralizing activity of SARS-CoV-2 variants and protects mice against BQ.1.1, XBB.1.5 and BA.2.86 challenge when administered intranasally post-exposure. The resistance of TRI2-2 to viral escape by most variants and the ability to deliver it directly to the upper airways highlight the potential of the multivalent miniprotein inhibitor as an alternative therapeutic modality. | |||||||||
| History |
|
-
Structure visualization
| Supplemental images |
|---|
-
Downloads & links
-EMDB archive
| Map data | emd_45969.map.gz | 483.4 MB | EMDB map data format | |
|---|---|---|---|---|
| Header (meta data) | emd-45969-v30.xml emd-45969.xml | 19.4 KB 19.4 KB | Display Display | EMDB header |
| Images | emd_45969.png | 59.8 KB | ||
| Filedesc metadata | emd-45969.cif.gz | 5.9 KB | ||
| Others | emd_45969_additional_1.map.gz emd_45969_half_map_1.map.gz emd_45969_half_map_2.map.gz | 256.5 MB 475.2 MB 475.2 MB | ||
| Archive directory | http://ftp.pdbj.org/pub/emdb/structures/EMD-45969 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-45969 | HTTPS FTP |
-Validation report
| Summary document | emd_45969_validation.pdf.gz | 817.5 KB | Display | EMDB validaton report |
|---|---|---|---|---|
| Full document | emd_45969_full_validation.pdf.gz | 817 KB | Display | |
| Data in XML | emd_45969_validation.xml.gz | 17.3 KB | Display | |
| Data in CIF | emd_45969_validation.cif.gz | 21 KB | Display | |
| Arichive directory | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-45969 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-45969 | HTTPS FTP |
-Related structure data
| Related structure data | ![]() 9cwpMC ![]() 9cwqC ![]() 9cwrC M: atomic model generated by this map C: citing same article ( |
|---|
-
Links
| EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
|---|
-
Map
| File | Download / File: emd_45969.map.gz / Format: CCP4 / Size: 512 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | sharpened map | ||||||||||||||||||||||||||||||||||||
| Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
| Voxel size | X=Y=Z: 1 Å | ||||||||||||||||||||||||||||||||||||
| Density |
| ||||||||||||||||||||||||||||||||||||
| Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
| Details | EMDB XML:
|
-Supplemental data
-Additional map: unsharpened map
| File | emd_45969_additional_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | unsharpened map | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: #2
| File | emd_45969_half_map_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: #1
| File | emd_45969_half_map_2.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-
Sample components
-Entire : SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder
| Entire | Name: SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder |
|---|---|
| Components |
|
-Supramolecule #1: SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder
| Supramolecule | Name: SARS-CoV-2 BA.2.86 RBD in complex with TRI2-2 minibinder type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1-#2 |
|---|---|
| Source (natural) | Organism: Sarbecovirus sp. |
-Macromolecule #1: BA.2.86 spike protein RBD
| Macromolecule | Name: BA.2.86 spike protein RBD / type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: ![]() |
| Molecular weight | Theoretical: 21.95882 KDa |
| Recombinant expression | Organism: Homo sapiens (human) |
| Sequence | String: NLCPFHEVFN ATRFASVYAW NRTRISNCVA DYSVLYNFAP FFAFKCYGVS PTKLNDLCFT NVYADSFVIK GNEVSQIAPG QTGNIADYN YKLPDDFTGC VIAWNSNKLD SKHSGNYDYW YRLFRKSKLK PFERDISTEI YQAGNKPCKG KGPNCYFPLQ S YGFRPTYG ...String: NLCPFHEVFN ATRFASVYAW NRTRISNCVA DYSVLYNFAP FFAFKCYGVS PTKLNDLCFT NVYADSFVIK GNEVSQIAPG QTGNIADYN YKLPDDFTGC VIAWNSNKLD SKHSGNYDYW YRLFRKSKLK PFERDISTEI YQAGNKPCKG KGPNCYFPLQ S YGFRPTYG VGHQPYRVVV LSFELLHAPA TVCGP |
-Macromolecule #2: Pan-variant miniprotein TRI2-2
| Macromolecule | Name: Pan-variant miniprotein TRI2-2 / type: protein_or_peptide / ID: 2 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: synthetic construct (others) |
| Molecular weight | Theoretical: 17.565787 KDa |
| Recombinant expression | Organism: ![]() |
| Sequence | String: ELEEQVMHVL DQVSELAHEL LHKLTGEELE RAAYFNWWAT EMMLELIKSD DEREIREIEE EARRILEHLE ELARKGGSEA LEELEKALR ELKKSTDELE RSTEELEKNP SEDALVENNR LIVENNKIIV EVLRIIAKVL KLEHHHHHH |
-Macromolecule #3: 2-acetamido-2-deoxy-beta-D-glucopyranose
| Macromolecule | Name: 2-acetamido-2-deoxy-beta-D-glucopyranose / type: ligand / ID: 3 / Number of copies: 2 / Formula: NAG |
|---|---|
| Molecular weight | Theoretical: 221.208 Da |
| Chemical component information | ![]() ChemComp-NAG: |
-Experimental details
-Structure determination
| Method | cryo EM |
|---|---|
Processing | single particle reconstruction |
| Aggregation state | particle |
-
Sample preparation
| Buffer | pH: 8 |
|---|---|
| Vitrification | Cryogen name: ETHANE |
-
Electron microscopy
| Microscope | FEI TITAN KRIOS |
|---|---|
| Image recording | Film or detector model: GATAN K3 (6k x 4k) / Average electron dose: 53.25 e/Å2 |
| Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
| Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Nominal defocus max: 1.8 µm / Nominal defocus min: 0.8 µm |
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
Movie
Controller
About Yorodumi



Keywords
Sarbecovirus sp.
Authors
United States, 1 items
Citation




Z (Sec.)
Y (Row.)
X (Col.)












































Homo sapiens (human)

Processing
FIELD EMISSION GUN
